Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDxHealth SA ADR (MDXH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: MDXH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $6.04
1 Year Target Price $6.04
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -16.4% | Avg. Invested days 37 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 188.09M USD | Price to earnings Ratio - | 1Y Target Price 6.04 |
Price to earnings Ratio - | 1Y Target Price 6.04 | ||
Volume (30-day avg) 6 | Beta -501433.88 | 52 Weeks Range 1.35 - 3.91 | Updated Date 09/17/2025 |
52 Weeks Range 1.35 - 3.91 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.79 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -34.98% | Operating Margin (TTM) -7.2% |
Management Effectiveness
Return on Assets (TTM) -7.92% | Return on Equity (TTM) -1552.23% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 239289869 | Price to Sales(TTM) 1.9 |
Enterprise Value 239289869 | Price to Sales(TTM) 1.9 | ||
Enterprise Value to Revenue 2.42 | Enterprise Value to EBITDA -2.73 | Shares Outstanding 49497300 | Shares Floating 35018869 |
Shares Outstanding 49497300 | Shares Floating 35018869 | ||
Percent Insiders 13.22 | Percent Institutions 43.66 |
Upturn AI SWOT
MDxHealth SA ADR
Company Overview
History and Background
MDxHealth SA ADR, originating from Belgium, focuses on developing and commercializing molecular diagnostic tests. Founded in 2003, it has evolved through strategic acquisitions and product launches to address unmet needs in urology and oncology.
Core Business Areas
- Urology: Development and commercialization of SelectMDx for Prostate Cancer, a urine-based molecular diagnostic test to reduce unnecessary biopsies.
- Oncology: Focus on developing tests for cancer detection and monitoring, with ongoing research and development efforts in other oncology areas.
Leadership and Structure
The company is led by a management team with experience in molecular diagnostics and commercialization. The organizational structure includes departments for R&D, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- SelectMDx for Prostate Cancer: A urine-based molecular diagnostic test that helps to identify men at higher risk of aggressive prostate cancer, reducing the need for unnecessary biopsies. Competitors include Exact Sciences (Oncotype DX Prostate), Myriad Genetics (Prolaris).
Market Dynamics
Industry Overview
The molecular diagnostics market is experiencing growth due to advances in genomics and personalized medicine. Increasing demand for non-invasive diagnostic tests is also driving growth.
Positioning
MDxHealth SA ADR is positioned as a provider of specialized molecular diagnostic tests in urology and oncology, with a focus on improving patient outcomes and reducing healthcare costs. The company's SelectMDx test offers a non-invasive alternative to traditional prostate biopsy.
Total Addressable Market (TAM)
The global molecular diagnostics market is estimated to be worth billions of dollars. MDxHealth is positioned to address a significant portion of the market for prostate cancer diagnostics, with increasing growth in the areas of bladder and kidney cancer testing as well.
Upturn SWOT Analysis
Strengths
- Proprietary molecular diagnostic technology
- Strong clinical validation data for SelectMDx
- Focus on unmet needs in urology and oncology
Weaknesses
- Limited product portfolio
- Reliance on single key product (SelectMDx)
- Relatively small commercial footprint compared to larger competitors
Opportunities
- Expansion into new geographic markets
- Development of new molecular diagnostic tests
- Partnerships with pharmaceutical companies and healthcare providers
Threats
- Competition from larger molecular diagnostic companies
- Changes in reimbursement policies
- Technological advancements by competitors
Competitors and Market Share
Key Competitors
- EXAS
- MYGN
- HOLX
Competitive Landscape
MDxHealth SA ADR competes with larger molecular diagnostic companies such as Exact Sciences (EXAS) and Myriad Genetics (MYGN). Its competitive advantage lies in its proprietary technology and focus on urology and oncology.
Growth Trajectory and Initiatives
Historical Growth: MDxHealth SA ADR has experienced revenue growth in recent years, driven by increased sales of SelectMDx.
Future Projections: Analyst estimates project continued revenue growth for MDxHealth SA ADR, driven by further adoption of SelectMDx and potential expansion into new markets.
Recent Initiatives: Recent strategic initiatives include expanding the sales force, securing reimbursement coverage for SelectMDx, and developing new molecular diagnostic tests.
Summary
MDxHealth SA ADR is a molecular diagnostics company focused on urology and oncology. Its key product, SelectMDx, addresses an unmet need in prostate cancer diagnosis. While the company faces competition from larger players, its proprietary technology and growth strategy position it for future success. There has been high growth in revenue, but the operating costs are quite high and should be addressed, so that future profits can be enjoyed by investors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Third-party Market Research
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MDxHealth SA ADR
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-11-04 | CEO & Executive Director Mr. Michael K. McGarrity | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 312 | Website https://mdxhealth.com |
Full time employees 312 | Website https://mdxhealth.com | ||
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection. It also offers genomic prostate score, which provides personalized genomic insights to physicians and patients navigating the complexities of prostate cancer diagnosis and treatment. The company sells its products through urology sales force consisting of direct sales representatives, strategic account managers, and regional sales managers. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.